Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01414283 · ClinicalTrials.gov registry record · Phase 1
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
A Phase 1 study, sponsored by Progenics Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT01414283 is a Phase 1 study that has completed, run by Progenics Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT01414283, a Phase 1 study, has completed, sponsored by Progenics Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label, dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. For all subjects, PSMA ADC will be administered in four repeating cycles.
Interventions
- DRUG PSMA ADC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2008-10 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01414283
The ClinicalTrials.gov registry entry for NCT01414283 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Progenics Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PSMA ADC is the first listed.
NCT01414283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01414283 about?
NCT01414283 is a clinical study titled "Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer". Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label, dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. For all subjects, PSMA...
What is the current status of trial NCT01414283?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2008-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01414283?
The interventions under investigation include: PSMA ADC (DRUG).
Who is sponsoring clinical trial NCT01414283?
This trial is sponsored by Progenics Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.